Take Action

“We’ve never been more able to use the tools of biomedical science to characterize disease, to understand its mechanisms and to impact patients then we are right now. We can model GNB1 and other diseases at a patient by-patient level and understand and treat their unique and shared features.” 

Terry Hébert, Professor of Pharmacology and Therapeutics, McGill University, Montréal, Canada